Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease

International Heart Journal

Volumn 55, Issue 6, 2014, Pages 482-483

  Imamura, Teruhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GLOMERULUS FILTRATION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINE OSMOLALITY; WATER PERMEABILITY; DIABETIC NEPHROPATHIES; FEMALE; MALE; METABOLISM; NEPHROTIC SYNDROME;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; AQUAPORIN 2; BENZAZEPINES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; NEPHROTIC SYNDROME;

EID: 84924806917     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-217     Document Type: Editorial

References (13)

1. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J 2014; 78: 844-52.
2. Kinugawa K, Imamura T, Komuro I. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. Clin Pharmacol Ther 2013; 94: 449-51.
3. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.
4. Sato E, Nakamura T, Amaha M, et al. Effect of tolvaptan on patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int Heart J (in press)
5. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993; 361: 549-52.
6. Sasaki S, Fushimi K, Saito H, et al. Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct. J Clin Invest 1994; 93: 1250-6.
7. Radin MJ, Yu MJ, Stoedkilde L, et al. Aquaporin-2 regulation in health and disease. Vet Clin Pathol 2012; 41: 455-70. (Review)
8. Imamura T, Kinugawa K, Fujino T, et al. Increased Urine Aquaporin- 2 Relative to Plasma Arginine Vasopressin Is a Novel Marker of Response to Tolvaptan in Patients With Decompensated Heart Failure. Circ J (in press)
9. Rai T, Sekine K, Kanno K, et al. Urinary excretion of aquaporin-2 water channel protein in human and rat. J Am Soc Nephrol 1997; 8: 1357-62.
10. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.
11. Imamura T, Kinugawa K, Minatsuki S, et al. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J 2014; 55: 131-7.
12. Imamura T, Kinugawa K, Minatsuki S, et al. Tolvaptan can improve clinical course in responders. Int Heart J 2013; 54: 377-81.
13. Imamura T, Kinugawa K, Ohtani T, et al. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study. Int Heart J 2014; 55: 264-7.